Objective To investigate prevalence and predictors of cardiovascular risk in pediatric liver transplant recipients using noninvasive markers of subclinical atherosclerosis: carotid intima-media thickness (cIMT) and aorta intimamedia thickness (aIMT).
Conclusion
Measures of long-term cardiovascular risk were associated with conditions that are more common in pediatric liver transplant recipients than nontransplanted peers, namely, diastolic hypertension and glucose intolerance. Larger, longitudinal studies are warranted to investigate whether cIMT could be useful for stratifying these patients' cardiovascular risk-and potential need for proactive intervention-during long-term follow-up. (J Pediatr 2018; 193:119-27 ).
I
n adult liver transplant recipients, cardiovascular disease is the third leading cause of death. 1 A key risk factor for cardiovascular events in adults, ie, myocardial infarction or stroke, is the post-transplant metabolic syndrome (PTMS)-a clustering of obesity, hypertension, dyslipidemia, and glucose intolerance. 2, 3 In pediatric liver transplant recipients, we have recently shown that PTMS and its components are common: 28% of children and young adults are overweight or obese, almost 35% have hypertension or prehypertension, 44% have prediabetes, and 37% have low high-density lipoprotein (HDL) cholesterol. 4 Survival well into adulthood is now the norm for these children. However, the impact of PTMS components on longterm cardiovascular health in these children is not known. Thus, elucidation of cardiovascular disease precursors and risk factors-particularly those that could be treated to prevent later morbidity-is a priority. 5 In nontransplanted children, carotid intima-media thickness (cIMT) has proven useful as a noninvasive method for predicting later cardiovascular risk. The cIMT is measured by ultrasound examination in the common carotid arteries, and standard measurement protocols have been endorsed by the American Heart Association for assessing subclinical atherosclerosis in pediatric clinical research. 6 The cIMT is a direct measure of arterial thickening, so it is appealingly applicable across populations that may have different risk factors for cardiovascular disease. Norms by age, height, and sex have been established. It changes reliably enough with treatment, for example, of hypertension or dyslipidemia, that it is used an endpoint in clinical trials. 6, 7 Most important, it predicts future cardiovascular events in adults. 6, 7 In this study, we measured the cIMT in pediatric liver transplant recipients with the aim of investigating whether the high prevalence of PTMS components is accompanied by endorgan evidence of early atherosclerosis. 6 We also assessed aortic intimal-medial thickness (aIMT), which may detect earlier subclinical atherosclerosis than cIMT. [8] [9] [10] There are no previous reports of aIMT in this population.
Methods
We performed a cross-sectional study of pediatric liver transplant recipients, aged 8-30 years at study visit, who were less than 18 years of age at first liver transplantation. At the study visit, all were at least 1 year from transplantation and on stable immunosuppressive regimens for at least 3 months. This study was approved by the University of California San Francisco's (UCSF) Committee on Human Research (UCSF CHR, IRB# 12-10290, 14-13939). After age-appropriate consent and assent were obtained, subjects were evaluated in UCSF's Pediatric Clinical Research Center or during elective inpatient admission for a surveillance liver biopsy, which were done only during clinically stable periods. Ultrasounds were done in UCSF's Pediatric Radiology suite. Visits were completed from September 2013 through March 2017. In addition to demographic factors like age and sex, we evaluated disease for which the participants were transplanted as a predictor; we classified patients by major disease categories (Table I) and by acute/ noncirrhotic disease (eg, acute liver failure, hepatoblastoma, urea cycle disorders) versus chronic/cirrhotic liver disease (eg, biliary atresia, progressive familial intrahepatic cholestasis [PFIC], Alagille syndrome, and alpha 1 antitrypsin deficiency).
For subjects younger than 18 years of age at the study visit, body mass index (BMI) percentile for age and sex was calculated based on 2000 Centers for Disease Control and Prevention growth chart data. 11 Subjects were classified as overweight for BMI percentile 85th-94th percentile and obese for BMI percentile of the 95th percentile or greater. 12 Increased waist circumference was considered at the 90th percentile or greater for age and sex. 13, 14 Systolic and diastolic hypertension were defined as use of antihypertensive agents or blood pressure at the 95th percentile or greater for sex, age, and height; prehypertension included those with blood pressure percentiles in the 90the-94th percentile. 13, 15 Subjects 18 years or older were classified according to adult guidelines. Overweight was considered as a BMI of 25-29.9 kg/ m 2 and obese at 30 kg/m 2 or greater. Increased waist circumference was 88 cm or greater for females and 102 cm or greater for males.
14 Hypertension was defined as use of antihypertensives or systolic blood pressure of 140 mm Hg or greater and a diastolic blood pressure of 90 mm Hg or greater. Prehypertension included those with a systolic blood pressure of 120 mm Hg or greater and a diastolic blood pressure of 80 mm Hg or greater. 13 Increased lipids for all subjects represented values at or above the 75th percentile for children and young adults. 13 Cutoffs were: triglycerides, 75 mg/dL or greater for children 9 year of age or younger and 90 mg/dL or greater for those 10 years of age or older; low-density lipoprotein (LDL) cholesterol of greater than 110 mg/dL, and total cholesterol of 170 mg/dL or greater. Low HDL was 40 mg/dL or less, which is in the 10th percentile or less. 13 Oral glucose tolerance testing was done with a weight-based glucose load; elevated fasting glucose was 100 mg/ dL or greater and impaired glucose tolerance was 140 mg/dL or greater at 2 hours, following American Diabetes Association definitions. 16 Homeostatic Model Assessment -Insulin Resistance, a measure of insulin resistance, was calculated as (fasting glucose × fasting insulin)/4.05. 17 We defined PTMS as the presence of 3 or more of the following: (1) increased waist circumference, (2) systolic or diastolic hypertension, (3) elevated triglycerides, (4) low HDL, and (5) elevated fasting glucose or impaired glucose tolerance. 13, 18 The cIMT was measured following American Heart Association pediatric guidelines for noninvasive assessment of subclinical atherosclerosis in clinical research. 6 Patients were positioned supine, with neck in slight extension and head turned 45°away from the side being measured. Using a General Electric Logiq E9 ultrasound machine (GE Health Care, Port Washington, New York), with a linear -MHz transducer, the intimal plus medial layer thickness of the common carotid artery far wall was measured 1-2 cm proximal to its bifurcation in 2 planes (anterior/oblique and lateral), on both the right and left carotids, by a trained sonographer. The mean cIMT represents the average of 4 measurements: far wall thickness on the right and left sides, and in true coronal and oblique coronal planes. 6 All measurements were verified at a radiology workstation (with manual adjustment of calipers if needed) by a single pediatric radiologist (Figure 1) .
The cIMT z-scores were calculated using sex-specific least mean squares (LMS) tables normalized for age in children 6-18, which is the range included in the LMS tables. LMS tables for the same cohort of >1000, nonobese, normotensive children are available normalized for height. 19 The cIMT measurements used in the generation of LMS tables were averaged far wall thickness of the common carotid artery, matching our measurement protocol. 20 To consider the predictors of relatively "elevated" cIMT within our cohort, we calculated cIMT z-scores, normalized for age and sex. The z-scores were calculated only for participants 18 years of age or older, to mirror the healthy children from which the norms were derived 19 ( Figure 2 ; available at www.jpeds.com). We divided our cohort into quartiles by cIMT z-score, and compared our top quartile to our lower 3 because there is no established cutoff for an "elevated" cIMT and we did not have a local control group against which to validate our z-scores.
The aIMT was measured in the distal abdominal aorta far wall, within 15 mm of the aortic bifurcation. 21 The z-scores for aIMT were not calculated given the lack of published LMS tables to allow for calculation. 21 
Statistical Analyses
Differences in the mean IMT between groups were first assessed using t tests allowing for unequal variances. When median and IQRs were reported for sample subsets or skewed groups, P values were derived from Kruskal-Wallis nonparametric testing. Associations between mean IMT and clinical predictors-demographics, medications, metabolic syndrome components-were then investigated using linear regression, with all models adjusted for sex and age, and cIMT additionally adjusted for height. 19, 22 For each association with cIMT, we also tested an age × predictor interaction term for significance, to evaluate whether the association magnitude varies by age-as has been reported in previous studies of pediatric cohorts that span childhood and adolescence 23 ( Table II) . The aIMT values were predicted from the fully adjusted linear regression model.
Results
This cross-sectional study included a diverse group of 88 pediatric liver transplant recipients at a mean age of 15.4 years and 11.2 years after first liver transplant ( Table I) . Four patients were transplanted for PFIC (PFIC1 = 2, PFIC2 = 2). Two had Alagille syndrome, and none were transplanted for familial hypercholesterolemia or cholesterol ester storage disease. Most patients were receiving calcineurin inhibitor monotherapy ( Table I) ; only 4 were receiving corticosteroids (2 on ≤5 mg/ day, 2 receiving 20 mg/day). None were receiving sirolimus. All 6 participants who were retransplanted had it done within 6 months of initial transplant-5 for hepatic artery thrombosis and 1 for cholangitis.
Overweight/obesity, systolic hypertension, and low HDL were each present in more than 25% of the cohort, as has been reported previously (Table I) . 4 Among the participants, 37% had at least 1 component of PTMS, 20% had 2, and 16% had 3 or more. Only 1 patient was on antihypertensive medications at the study visit, with controlled hypertension. None were on lipid-lowering or antihyperglycemic medications.
The mean cIMT in the cohort was slightly higher in males than females. It increased with age, after controlling for sex and height (Table II) . When age at visit was divided into years before and after liver transplantation, the cIMT increased for each year since transplant (0.005 mm; 95% CI, 0.002-0.009; P = .006) and remained associated with age at transplantation (0.005 mm per year of age; 95% CI, 0.001-0.009; P = .02), with no interaction term between the 2 predictors (P = .55). Thus, the rate of cIMT increase per year thus seemed to be the same before and after transplantation. All subsequent cIMT analyses were adjusted for sex, age at visit, and height.
The cIMT was significantly higher in patients transplanted for chronic/cirrhotic liver disease (Table II) but did not differ significantly by Hispanic ethnicity, type of transplant (whole vs split/partial), or donor type (living vs deceased) in these adjusted models (data not shown). cIMT was slightly lower in multiracial subjects (−0.044 mm; 95% CI, −0.077 to −0.008; P = .02) compared with white subjects with no other significant differences by race (data not shown for other categories). The cIMT was not associated with corticosteroid use at study visit (n = 4), history of any acute rejection, number of acute rejection episodes, or diagnosis of chronic rejection (n = 5) or kidney/liver laboratory tests at study visit (serum creatinine, estimated glomerular filtration rate by Schwarz equation, aspartate aminotransferase, alanine aminotransferase, or total bilirubin at study visit; data not shown).
The mean cIMT was significantly lower in the 9 patients on cyclosporine than those on tacrolimus (Table II) . Those on cyclosporine were of similar age at visit (median 16.9 years vs 15.8 years; P = .38) but significantly farther from transplant .53]; P = .007 for both comparisons). There was no difference in number of previous acute rejection episodes (median 1 for each group; P = .93). In sensitivity analyses, excluding the 4 patients on corticosteroids, those on cyclosporine still had a significantly lower cIMT at study visit than those on tacrolimus (−0.184 mm; 95% CI, −0.347 to −0.020; P = .03), and there was still a significant interaction with age (P = .03).
In examining associations between PTMS components and cIMT, we considered interactions between each cardiovascular risk factor and age. 23 The cIMT was significantly higher in participants with diastolic hypertension and elevated A B Figure 1 . A, Longitudinal ultrasound image of the right common carotid artery. After magnifying the IMT (inset boxes), it is seen that the sonographer's calipers (crosses) are accurately placed at the edges of the intima and media. B, Longitudinal ultrasound examination of the inferior abdominal aorta. After magnifying the IMT (inset box), it is seen that the sonographer's calipers (crosses) are not accurately placed, with one of the calipers being slightly too far into the lumen of the vessel. Therefore, the IMT was manually remeasured by the radiologist between the arrow tips. AO, aorta; CCA, common carotid artery; RT, right. triglycerides, as categorized by age-specific criteria, in univariate analysis (Table II) .
The cIMT increased in tandem with diastolic blood pressure and triglycerides in fully adjusted models ( Table II) . The cIMT was also associated with HDL, although unexpectedly increases in HDL were associated with increases in cIMT. In models considering PTMS components categorically as "normal" vs "abnormal," patients with elevated triglycerides for age had higher cIMT (Table III; available at www.jpeds.com). Sensitivity analyses excluding retransplanted patients did not impact variable significance or coefficient magnitude.
In our subjects 18 years of age or younger at study visit (n = 67), the median cIMT z-score was 1.94 (IQR, 0.88-2.58). Of interest, 57% of patients transplanted for chronic/ cirrhotic liver disease had a c-IMT z-score of 2 or more, compared with 32% of those transplanted for acute/ noncirrhotic disease. Comparing the patients with cIMT z-scores in the highest quartile (≥2.59) with those in the lower 3 revealed no differences in age at or years since transplantation, race/ethnicity, transplantation for chronic/ cirrhotic liver disease, years of immunosuppression, or number of previous acute rejection episodes (data not shown). Across cIMT z-score quartiles, there were no differences in the prevalence of overweight/obesity, systolic or diastolic hypertension, dyslipidemias, glucose intolerance, or PTMS (data not shown).
All 4 of the 18-year-old or younger subjects with a history of chronic rejection had a cIMT z-score in the highest quartile, compared with 20% of those without chronic rejection (P < .001). These ranged from 8.9 to 13.4 years of age at study visit, and were 6.4-11.5 years from transplant. None were on corticosteroids or sirolimus. One had borderline high triglycerides and systolic prehypertension, but none had diastolic hypertension.
Paralleling 1 previous study, both patients with PFIC1 in our cohort had cIMT z-scores in the highest quartile despite being normotensive, not obese, with normal lipids, and on tacrolimus monotherapy. 24 None of the PFIC3 or Alagille syndrome patients had cIMT z-score in the highest quartile (n = 4; z-score range, 0.89-1.80).
As a sensitivity analysis, we also calculated cIMT z-scores normalized for height and sex. 19 The age and height-normalized z-scores correlated tightly (r = 0.99; P < .001). Repeating these analyses using height-normalized z-scores did not change any of the reported relationships or quartile categorization. For variables that had a significant interaction with age (P < .10), the reported coefficient, 95% CI, and P value accounts for that interaction. †P < .05 for interaction with age. ‡P = .07 for interaction with age. §P = .06 for interaction with age. ¶See Table III On univariate analysis, the aIMT increased significantly with age (0.009 mm per 1 year; 95% CI, 0.000-0.018; P = .05), height (0.013 mm per 5 cm height; 95% CI, 0.000-0.025; P = .05), and sex (0.008 mm higher in males than females; 956% CI, −0.001 to 0.169; P = .053). Of interest, both age at transplantation and years since transplantation were highly associated with increasing aIMT (Table IV) and there was a significant statistical interaction between the 2 variables (P = .03). This suggests that aIMT may increase at a different rate post-transplant, depending on the age at transplantation (Figure 3 ; available at www.jpeds.com). All subsequent analyses were adjusted for sex, age at transplantation, years since transplantation, and an interaction between the latter 2 variables.
In adjusted analyses, aIMT increased with stimulated glucose (2-hour glucose during oral glucose tolerance test) and Homeostatic Model Assessment -Insulin Resistance ( Table IV) . The aIMT was significantly higher in subjects that had glucose intolerance (2-hour glucose ≥140 mg/dL). The aIMTs increase with increasing diastolic blood pressure had borderline statistical significance. In a model limited to patients 20 years of age or younger for whom blood pressure percentiles could be calculated (n = 66), the aIMT did significantly increase with increasing diastolic blood pressure percentile (0.010 mm per 5-percentile diastolic blood pressure increase; 95% CI, 0.000-0.021; P = .05) but not systolic blood pressure percentile.
The aIMT retained a significant association with increasing stimulated glucose and increasing Homeostatic Model Assessment -Insulin Resistance in fully adjusted models. In models considering PTMS components categorically as "normal" vs "abnormal," patients with glucose intolerance had a significantly higher aIMT than those with normal glucose tolerance ( Table III) . Sensitivity analysis excluding retransplanted patients did not impact variable significance or coefficient magnitude. *Statistically significant interaction between these 2 variables, P = .02 in sex-adjusted analysis. All P values from linear regression models. †Adjusted for interaction, P = .06 for the interaction term. ‡See Table III for fully adjusted model, incorporating categorical predictors instead of continuous.
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Discussion
This cohort of pediatric liver transplant recipients is the largest in which cIMT has been measured and the first to report on aIMT. In this cohort, increasing diastolic blood pressure, triglycerides, and transplant for chronic/cirrhotic liver disease were associated with increasing cIMT. 25 Higher aIMT was associated with glucose intolerance, and with increasing diastolic blood pressure percentile in recipients 20 years of age or younger, but not with transplant indication. We have recently shown that pediatric liver transplant recipients are at an increased risk for diastolic hypertension and glucose intolerance compared with nontransplanted peers 4 ; this analysis connects those morbidities with a potential long-term risk of cardiovascular disease.
Previous research, and published guidelines, have not included pediatric liver transplant recipients as an at-risk group for long-term cardiovascular disease, 13, 26, 27 but these conclusions were not based on robust evidence. The 2 previous studies of cIMT in pediatric liver transplant recipient failed to demonstrate any correlation between cIMT and any metabolic syndrome components. However, both studies were very small (n = 9 and n = 31), and likely did not have adequate power to detect significant correlations. 26, 27 Although our sample size is still limited, we did detect correlations between some PTMS components-notably diastolic hypertension, hypertriglyceridemia, and glucose intolerance-and markers of later cardiovascular risk. Our analysis does suggest that larger, longitudinal studies are warranted to determine whether pediatric liver transplant recipients-or potentially subsets depending on transplant indication-are at risk for increased cIMT or aIMT and early cardiovascular events. Prospective studies will be key for developing evidence-based screening protocols and preventive strategies to ameliorate long-term cardiovascular risk in these children and young adults. 28 Also important is that obesity was not a reliable predictor of cIMT or aIMT in our cohort. It is possible that something related to the liver disease before transplantation, the transplant itself, or the immunosuppression exposure after it has a stronger impact on cIMT and aIMT than current obesity or full-blown metabolic syndrome in our patients. Our data suggested, for example, that the aIMT increased at a different rate post-transplant depending on the age at transplantation. Patients with chronic liver disease often have hyperdynamic cardiovascular function and relatively low blood pressurewhich may impact vascular stress and thickness pretransplant. Post-transplant, those requiring higher levels of calcineurin inhibitors to suppress rejection may have more hypertensionagain impacting vascular stress and thickness. However, repeated measures in patients from the time of transplant are needed to confirm this and understand its significance. Medications used routinely post-transplant-especially calcineurin inhibitors and corticosteroids-can cause transient conditions that may accelerate cIMT increase: hypertension, dyslipidemia, and glucose intolerance. Patients with chronic rejection had relatively elevated cIMT scores compared with others in the cohort, which may represent an impact of previous or intermittent hypertension or dyslipidemia related to immunosuppression. A recent systematic review found that pediatric kidney transplant recipients have higher cIMT than healthy controls after adjusting for hypertension-again supporting the hypothesis that immunosuppression medications, which are the same as those used in liver transplant recipients-may be contributing to risk. 29 More detailed, prospective tracking of medication exposure will be helpful to evaluate whether arterial thickness might increase with high levels-and concurrent hypertension, dyslipidemia, or other risk factors-and then regress if exposure is low and stable. Our finding that patients on cyclosporine had lower cIMT than those on tacrolimus suggests this pattern. Although these patients were relatively far from transplant, they remained on cyclosporine because they had been clinically stable at low doses; none were hypertensive at study visit, only 1 of 9 was overweight with elevated triglycerides.
The contribution of genetic diseases that affect both the liver and the cardiovascular system also warrants further study. One previous case series identified the same pattern we observed: higher than expected cIMTs in patients with PFIC1, but normal range cIMT in patients with Alagille syndrome. 24 Nagasaka et al found that children with PFIC1 and PFIC2 had high oxidized LDL, dense LDL particles enriched in triglycerides, and low HDL-an atherogenic profile. In contrast, children with Alagille syndrome had high levels of lipoprotein X and HDL with minimally elevated oxidized LDL-a pattern protective against atherosclerosis.
24
PFIC1 has been associated with decreased farnesoid X receptor activity in intestinal cells. 30 Interestingly, farnesoid X receptor is also expressed in vascular endothelium, some macrophages, and other organs; a role in atherosclerosis has been posited through mechanisms, including changes in lipid trafficking, vasoconstriction, and inflammation. 31 Liver transplantation would presumably ameliorate farnesoid X receptor dysfunction in the livers of patients with PFIC1, but its persistent dysfunction in other tissues is one possible explanation for elevated cIMT in these patients.
Although we did identify diastolic blood pressure, triglycerides, and glucose intolerance as correlates of subclinical atherosclerosis in our cohort, we did not identify associations of cIMT and aIMT with other cardiovascular risk factors that have been reported in nontransplanted children-including BMI, systolic blood pressure, and LDL cholesterol levels. 10 A larger cohort may be required to detect significant correlates. Because cIMT and aIMT measurements approach the limits of precision for ultrasound imaging, the range of potential measurements is limited-limiting power to detect correlations in our relatively small sample. One radiologist manually adjusted calipers on all measurements to enhance consistency, although the best method for determining carotid boundaries-manual vs automatic using computer algorithms-remains a topic of debate. 32 We found that aIMT was more technically difficult to measure because of bowel gas, and manual calibration often led to significantly different measurements (Figure 1) . There are no established norms for aIMT and less specific guidelines on standardizing measures, making validation of our own protocol and measures more difficult. A lack of cIMT and aIMT correlation has also been reported in larger studies of healthy pediatric patients. 10, 21 Previous investigators have posited that this poor correlation may be because cIMT and aIMT change at different rates at different stages of life, and that hemodynamics or even local metabolic milieu may play a role. We found that the rate of aIMT change was different before and after transplantation, which could reflect a transplant-mediated change in hemodynamics, unknown circulating serum factors, or the impact of immunosuppression. In short, aIMT remains intriguing, but determining its usefulness as a marker of cardiovascular risk-both in the general pediatric population and for transplant recipients-would require longitudinal and larger studies.
Our assessment of renal function was limited to indirect measures, including creatinine and a calculated glomerular filtration rate; a measured glomerular filtration rate would more accurately reflect kidney function in these children, and should be included in future studies as feasible. Finally, larger studies have shown that the relationships between cIMT, metabolic syndrome components, and cardiovascular risk strengthen in young adulthood. 19, 33 As our cohort ages, these associations may emerge more robustly.
This analysis demonstrated an association between diastolic hypertension, triglycerides, and glucose intolerance, and measures of subclinical atherosclerosis in pediatric liver transplant recipients. Longitudinal studies in a larger group of patients, ideally with control comparisons, will be needed to determine the usefulness of cIMT for predicting and after the evolution of cardiovascular risk in pediatric liver transplant recipients. The cIMT would be just 1 tool that we could use to more accurately stratify these patients' cardiovascular riskand potential need for proactive intervention-during longterm follow-up. 34 Figure 2 . Distribution of cIMT z-scores for subjects 18 years of age or younger at study visit, normalized for subject age and sex. *Adjusted for interaction with age at visit, P < .05 for all interaction terms. †Adjusted for interaction, P = .06 for the interaction term.
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